NCT06769126: An ongoing trial by SWOG Cancer Research Network
This trial is ongoing. It must report results 4 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06769126 |
|---|---|
| Title | PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 8, 2025 |
| Completion date | Dec. 31, 2028 |
| Required reporting date | Dec. 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | None |